Supporting prostate cancer research

TheraP: A randomised phase 2 trial of 177Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer.

Prof Michael Hofman, Peter MacCallum Cancer Centre.

Lutetium-177 PSMA radionuclide therapy (Lu-PSMA) is a new treatment for advanced prostate cancer. Lu-PSMA is a radioactive molecule that specifically attaches to cells with high amounts of PSMA on the surface of the cells. This allows the radioactivity to be delivered mainly to the prostate cancer cells wherever they have spread, while sparing most normal tissues. Previous small studies of Lu-PSMA showed promising activity in patients with advanced prostate cancer.

This randomised trial compare Lu-PSMA with a type of chemotherapy called cabazitaxel, which is the standard treatment for advanced prostate cancer when other treatments have stopped working. Half the participants received Lu-PSMA and half received cabazitaxel. This study will provide further information about the risks and benefits of Lu-PSMA compared with cabazitaxel in men with prostate cancer.

This trial is no longer recruiting participants.

Join us today!

Pathfinder is a unique prostate cancer research register that enables prostate cancer survivors to participate in research for a brighter future with their loved ones.

It will enable researchers to save valuable time and money recruiting participants for their projects, so that they can spend more time delivering health benefits to those in need. Click the button to the right to register!